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Abstract: There are common clinical scenarios in chronic heart disease where no randomized
controlled data exist to guide management, and it is likely that well-designed observational studies
will have to be used to inform clinical practice. Showing the clinical applicability of this type of
study design, using record linkage of population electronic health records, we have provided key
observational evidence that use of renin–angiotensin-system (RAS) blockers is associated with better
outcomes in patients with aortic stenosis and that metformin could be used safely as an antiglycemic
drug in patients with diabetes and heart failure. Each of these pieces of underpinning research has
made a major contribution to relevant international clinical practice guidelines, helped the Food and
Drug Administration in their decision making and changed prescribing practice.
Keywords: population electronic health records; renin–angiotensin system blockers; aortic stenosis;
metformin; heart failure
1. Background
The digitization of health records has created an opportunity in the secondary use of routinely
collected electronic health records (EHRs) for public health research in large-scale studies.
There are several common and important clinical scenarios in chronic heart disease, and it is
difficult to outline an evidence-based treatment strategy because there have been no randomized trials
that have adequately explored the risks and benefits of these drug therapies. Furthermore, due to
the current research landscape, it is unlikely that large, adequately powered, randomized controlled
trials (RCTs) will be undertaken in the future. In these populations, no RCT-level data exist to guide
management, and clinicians can only be guided by well-designed observational studies.
Demonstrating one potential approach to this problem, we have linked our EHRs with cardiac
investigations including echocardiograms and utilized these enriched EHRs to provide key population
cohort data to demonstrate the safe use of drugs in conditions in which their use had previously been
avoided due to what were presumed to be classical contraindications for use, described in the British
National Formulary and the manufacturers’ prescribing information (Physicians’ Desk Reference) in
two case scenarios: “Use of renin angiotensin system (RAS) blockers are contraindicated for use in
patients with aortic stenosis” (AS); and “metformin should be used with caution in patients with type
2 diabetes mellitus (T2DM) and co-existing heart failure” (HF). Because of these contraindications,
these drugs have been little studied in RCTs. Despite the prevailing clinical treatment paradigms at the
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time, there was no definitive trial evidence to support these contraindications, and importantly, there
were plausible reasons to believe that patients might actually derive benefits from these treatments.
2. Scenario 1: RAS Inhibition in Aortic Stenosis
AS is the most common form of valvular heart disease in the western world and affects 2% to 4%
of adults older than age 65 years. It is typically a progressive disease with a long asymptomatic phase,
but once symptoms develop, the prognosis is poor, with 50% mortality at one year [1]. In patients with
asymptomatic AS, hypertension is a common comorbidity found in up to 78% of patients, associated
with a 56% higher rate of cardiovascular events and two-fold increased mortality [2]. There was
uncertainty about what drugs should be used to treat concomitant hypertension in AS, especially
concerning the use of RAS blockers that were perceived as being relatively contraindicated due to their
vasodilatory effect. However, it is increasingly recognized that AS incorporates a disease process that
extends beyond the valve itself, leading to an aortic valvular ‘heart’ disease with adverse left ventricular
modeling, which may be related to the RAS. We previously reported the findings of population-based
data that investigated the impact of RAS blockers on outcomes in AS [3]. In brief, the Health
Informatics Centre dispensed prescribing, morbidity and mortality database for the population of
Tayside, Scotland was linked through a unique patient identifier to the Tayside echocardiography
database. This population-based research identified 2117 patients with AS, with a mean follow-up
of 4.2 years. This cohort featured 1585 (75%) patients with nonsevere and 532 (25%) with severe AS.
A total of 699 patients were on RAS blockers. The study showed that the use of RAS blockers was
associated with a significant reduction in cardiovascular events (HR: 0.77, 95% confidence interval: 0.65
to 0.92, p < 0.0001) and all-cause mortality (HR: 0.76, confidence interval: 0.62 to 0.92, p < 0.0001) [3].
This Tayside study was the first to provide key observational evidence that ACEI or ARBs are not only
safe to use but may be associated with improved outcomes. These protective effects of RAS in AS have
since been confirmed by other groups [4,5].
3. Scenario 2: Patients with Type 2 Diabetes and Heart Failure: Use of Metformin and Importance
of Glycemic Control
In HF cohorts, the prevalence ranges from 10 to 47%, and in patients with T2DM, the prevalence
ranges from 9 to 22% [6]. T2DM is independently associated with a greater risk of death and
rehospitalization. Treating patients with concomitant HF and T2DM can be challenging. It has been
difficult to outline an evidence-based diabetic treatment strategy as there have been no randomized
trials adequately exploring the risks and benefits of diabetic therapies in this population. Additionally,
controversy exists regarding the importance of glycemic control in patients with T2DM and HF
based on conflicting reports using single-baseline glycosylated hemoglobin (HbA1c). Metformin
was previously contraindicated in patients with HF because of concerns of lactic acidosis, although
this may reflect previous experience with phenformin-associated lactic acidosis. With respect to this,
we published a retrospective population cohort study utilizing record linkage of EHRs of the incidence
of contraindications to the use of metformin and the proportion that discontinued metformin treatment
following the development of a contraindication in patients with T2DM from January 1993 to June
1995 [7]. The study showed that 24.5% of patients prescribed metformin had contraindications to
its use. The development of contraindications rarely resulted in the discontinuation of metformin
therapy, and lactic acidosis was rare (one episode of lactic acidosis in 4600 patient years). In another
study examining the use of metformin in T2DM and HF, we found that among 427 T2DM patients
with incident HF, fewer deaths occurred in metformin users, alone or in combination with the
sulfonylurea monotherapy cohort at one year (HR of 0.59 (0.36–0.96)) and over long-term follow-up
(HR, 0.67 (0.51–0.88)) [8].
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To explore the importance of glycemic control, we previously published a study reporting
the relationship between time-weighted mean HbA1c and all-cause death after HF diagnosis in a
population cohort of 1447 patients with HF diagnosed after T2DM that also had HbA1c measurements.
The Cox regression model with an adjusted hazards ratio reported a U-shaped curve between HbA1c
and mortality in patients with T2DM and HF, with the lowest risk in patients with moderate glycemic
control (HbA1c 7.1–8.0% HR 1.0) [9].
In this report, we explored the impact of our published key observational evidence on these two
scenarios. Specifically, we explored their potential contribution to changes in prescribing practice and
in relation to the publication of the research findings and changes in clinical practice guidelines.
4. Methods
This was a retrospective, population-based, longitudinal study conducted in the population of
Tayside, Scotland (approximately 400,000) using the dispensed prescribing database maintained by the
Health Informatics Centre (HIC), University of Dundee and NHS Tayside. This contains records of all
dispensed community prescriptions dating back to 1993. Clinical information was collected according
to the national clinical dataset for the care of patients in Scotland. Datasets available from HIC also
included hospital discharge data, biochemistry data, mortality data, sociodemographic descriptors
and other data that are linked by a unique 10-digit patient identifier, the community health index
number, that is used for all healthcare activities in Tayside. Access to the anonymized and validated
clinical datasets was administered by HIC using established protocols approved by the Research Ethics
Committee in Tayside.
In Case Scenario 1, all patients with a diagnosis of moderate to severe AS between January 2000 and
December 2019 were identified from the Tayside echocardiogram database. The diagnosis and severity
of AS were ascertained by the British Society of Echocardiography accredited echocardiographers at
the time of the scan. We then identified those who were newly prescribed a RAS blocker in this cohort
during the study period. The prescribing of RAS blockers constituted at least 2 prescriptions of an
angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker.
In Case Scenario 2, we identified all Tayside residents with a diagnosis of both T2DM and HF
between January 2000 and December 2019. We then identified all those who were newly treated with
metformin during the study period. The prescribing of metformin constituted at least 2 prescriptions
of metformin.
4.1. Relationship to Clinical Practice Guidelines and Drug Regulations
To help identify any changes in prescribing practice, we will display prescribing data in relation to
the timing of dissemination of the research findings in scientific presentations at meetings, publications
and when the research was included in clinical practice guidelines.
4.2. Impact on Clinical Practice Guidelines
Our research has impacted international clinical practice guidelines that are used by healthcare
decision-makers to optimize and improve care. Our research provided the key underpinning evidence
used in their recommendations for use in patients with aortic stenosis. Hypertension is common
and harmful in patients with AS. Medical therapy is now strongly recommended (Class I; Level
B). Our research [3] was cited as the underpinning evidence for the use of RAS blockers as ‘an
antihypertensive agent in patients with AS’ (Class 1, Level of Evidence: B) in the 2014 ACC/AHA
guidelines [10].
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Our research has also impacted clinical practice guidelines for T2DM and HF. Our EHRs research
demonstrated that metformin was not only safe to use [6] but may be associated with improved
survival in patients with T2DM and HF [7]. Our research provided the evidence that guided the
recommendation by international CPGs regarding the safe use of metformin in achieving glycemic
control in these patients, including the 2011 update to the National Heart Foundation of Australia
and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and
management of chronic heart failure [11] and 2016 American Heart Association Scientific Consensus
Statement and 2017 ACC/AHA/HFSA Statement [12,13]. We have provided the underpinning evidence
for practice advice on glycemic control in this vulnerable patient group, and the guidelines recommend
‘a target range of HbA1c 7% to 8% for most patients with HF’ [13–15].
4.3. Impact on Regulatory Guidance
We also explored if our research impacted decision making by regulatory authorities. In this
respect, our research demonstrating the safety of metformin was instrumental in the lifting of warnings
on the use of metformin by the FDA in 2016 [16].
5. Results
Case Scenario 1. We found an increase in the number of prescriptions of RAS blockers in patients
with moderate to severe aortic stenosis, with an increase in the percentage of patients with moderate
to severe AS on RAS blockers (Figure 1). Figure 1 also indicates the timing of local/international
presentations [17,18], publication of the results and mention in clinical practice guidelines.
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Figure 1. Prescribing of ACEI/ARB in patients with moderate to severe aortic stenosis in Tayside
between 2000 and 2019.
Case Scenario 2. We found an increase in the number of prescriptions of metformin in patients with
T2DM and HF, with an increase in the percentage of patients with moderate to severe AS on metformin
(Figure 2). Figure 2 also indicates the timing of local presentation [19], international presentation [20],
publication of the results and entry in clinical practice guidelines.
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Figure 2. Prescribing of metformin in patients with heart failure and type 2 diabetes in Tayside between
2000 and 2019.
6. Discussion
In this report, we have shown an increase in prescribing both RAS blockers in patients identified
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increase in the use f both drug classes in the two case scenarios over the years. e observatio al
nature of the study means that we cannot confid ntly attribute this change in prescribing practice to
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